Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a RSVpreF Vaccine Respiratory Syncytial Virus Challenge Study in Healthy Adults
2020-003887-21Phase 2Unknown
- Sponsor
- hVIVO
- Start
- Sep 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing RSVpreF vaccine with Placebo (2 arms). Primary endpoints: Primary endpoint family: reduction in RSV infection or disease measures and Reduction in incidence of RSV infection or disease. Status: unknown.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2020-003887-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003887-21.